Evercore Bullish on Union Pacific Amid Strong Volume Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 28 2026
0mins
Source: Yahoo Finance
- Analyst Sentiment: As of March 24, 2026, approximately 70% of analysts maintain bullish ratings on Union Pacific Corporation (NYSE:UNP), reflecting strong market confidence in its performance, with a consensus price target of $275 implying a 14.74% upside.
- Strong Performance Growth: Evercore highlights that Union Pacific continues to demonstrate robust operational performance supported by strong volume growth and solid margins, showcasing its competitiveness in the railroad and freight transportation sector.
- Merger Outlook Impact: Analysts suggest that Union Pacific's stock may remain range-bound until clarity is achieved regarding its proposed merger with Norfolk Southern; however, if the deal closes, significant upside is projected for the stock.
- Relative Valuation Advantage: The stock is currently trading at a discount to all but one of its peers, indicating its attractiveness in the market, despite some AI stocks potentially offering greater upside potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVR
Wall Street analysts forecast EVR stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 357.520
Low
342.36
Averages
389.87
High
425.00
Current: 357.520
Low
342.36
Averages
389.87
High
425.00
About EVR
Evercore Inc. is an investment banking and investment management company. The Company's segment includes Investment Banking & Equities and Investment Management. Investment Banking & Equities includes the investment banking business through which it provides advice to clients on significant mergers, acquisitions, divestitures, shareholder activism, and other strategic corporate transactions, with a particular focus on advising multinational corporations and private equity firms on large, complex transactions. It also provides liability management and restructuring advice to companies in financial transition, as well as to creditors, shareholders, and potential acquirers. Investment Management includes the wealth management business, through which it provides investment advisory, wealth management and fiduciary services for high-net-worth individuals and associated entities, and the private equity business, which holds interests in private equity funds not managed by the Company.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sandisk to Join Nasdaq-100 on April 20, 2025
- Inclusion in Nasdaq-100: Sandisk is set to join the Nasdaq-100 on April 20, 2025, replacing Atlassian, which underscores its strong demand in the data storage solutions sector, despite Wall Street's general view of overvaluation.
- Stock Performance and Analysis: The stock has surged over 2,700% in the past year, currently priced at $921, with analysts' median target price at $843, indicating an 8% downside risk; however, some analysts project a potential rise to $2,600, suggesting a 182% upside.
- Market Share Growth: Sandisk gained 2 percentage points in the NAND flash market over the past year, ranking fourth, yet outpacing industry leader Samsung, highlighting its competitiveness amid soaring AI data center demand.
- Strong Financial Performance: In Q1 2023, Sandisk's sales jumped 61% to $3 billion, with non-GAAP earnings soaring 404% to $6.20 per share; while future supply-demand imbalances pose risks, the current growth momentum renders its valuation reasonable.
See More
Sandisk Stock Soars 2,700% Ahead of Nasdaq-100 Inclusion
- Stock Surge: Sandisk's stock has surged 2,700% over the past year, primarily driven by strong demand for its data center storage solutions, and its upcoming inclusion in the Nasdaq-100 is expected to further boost its stock price.
- Market Share Growth: Although Sandisk ranks fourth in the NAND flash market, it gained 2 percentage points of market share over the past year, indicating its increasing competitiveness amid surging AI data center demand.
- Strong Financial Performance: In the January quarter of 2023, Sandisk's sales jumped 61% to $3 billion, while non-GAAP adjusted earnings soared 404% to $6.20 per share, reflecting the company's profitability in a rapidly growing market.
- Future Risks: Despite the current supply shortage driving price increases, analysts warn that increased production capacity may lead to a supply glut in the future, potentially causing NAND prices to fall significantly, prompting investors to approach the stock's high valuation with caution.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
US Blockade of Strait of Hormuz Strains Relations with China and India
- Strained US-China Relations: The US blockade of the Strait of Hormuz not only intensifies pressure on Iran but also risks destabilizing the fragile relationship with China, particularly with a summit between Trump and Xi Jinping approaching, which could impact economic cooperation and strategic stability.
- Rising Energy Risks for India: After resuming oil and gas imports from Iran, India faces a conflict between US policy and its economic interests, especially regarding energy supply vulnerabilities, which may lead to further deterioration in relations with Washington.
- China's Resilience: Despite the energy shock, China's substantial oil stockpiles and diversified energy mix allow it to manage the situation relatively well, with expectations that it can compensate for lost Iranian oil through alternative sources and increased coal usage.
- India's Strategic Shortcomings: India's lack of strategic reserves for liquefied petroleum gas poses significant economic risks, particularly if Middle Eastern supplies are disrupted, potentially leading to shortages for households and businesses, which could affect social stability.
See More
Financial Stocks Underperform, Investors Remain Cautious
- Industry Challenges: Financial stocks have collectively dropped 8.8% over the past six months due to an unpredictable interest rate and inflation environment, significantly underperforming the S&P 500's 2.8% decline, indicating investor concerns about the sector's outlook.
- State Street's Lackluster Performance: With a market cap of $35.75 billion, State Street has seen only 3.6% annual revenue growth over the past five years, and its EPS growth of 9.1% annually falls short of the peer group average, reflecting limited growth potential compared to smaller competitors.
- Raymond James's Strong Growth: Raymond James, valued at $28.26 billion, has achieved an impressive 11.7% annual revenue growth over the last five years, bolstered by share buybacks that accelerated EPS growth, showcasing management's expertise in identifying profitable investments.
- Evercore's Market Share Gains: Evercore, with a market cap of $11.93 billion, has reported a remarkable 25.9% annual revenue growth over the last two years, with EPS increasing by 50.2% annually, indicating its success in capturing market share during the current cycle.
See More
Sandisk to Join Nasdaq-100 on April 20, 2025
- Inclusion in Nasdaq-100: Sandisk is set to join the Nasdaq-100 on April 20, 2025, replacing Atlassian, which underscores its strong demand in the data storage solutions sector, despite Wall Street's general view of overvaluation.
- Stock Performance and Analysis: The stock has surged over 2,700% in the past year, currently priced at $921, with analysts' median target price at $843, indicating an 8% downside risk; however, some analysts project a potential rise to $2,600, suggesting a 182% upside.
- Market Share Growth: Sandisk gained 2 percentage points in the NAND flash market over the past year, ranking fourth, yet outpacing industry leader Samsung, highlighting its competitiveness amid soaring AI data center demand.
- Strong Financial Performance: In Q1 2023, Sandisk's sales jumped 61% to $3 billion, with non-GAAP earnings soaring 404% to $6.20 per share; while future supply-demand imbalances pose risks, the current growth momentum renders its valuation reasonable.
See More
Sandisk Stock Soars 2,700% Ahead of Nasdaq-100 Inclusion
- Stock Surge: Sandisk's stock has surged 2,700% over the past year, primarily driven by strong demand for its data center storage solutions, and its upcoming inclusion in the Nasdaq-100 is expected to further boost its stock price.
- Market Share Growth: Although Sandisk ranks fourth in the NAND flash market, it gained 2 percentage points of market share over the past year, indicating its increasing competitiveness amid surging AI data center demand.
- Strong Financial Performance: In the January quarter of 2023, Sandisk's sales jumped 61% to $3 billion, while non-GAAP adjusted earnings soared 404% to $6.20 per share, reflecting the company's profitability in a rapidly growing market.
- Future Risks: Despite the current supply shortage driving price increases, analysts warn that increased production capacity may lead to a supply glut in the future, potentially causing NAND prices to fall significantly, prompting investors to approach the stock's high valuation with caution.
See More
Teva's FDA Approval of Long-Acting Drug Could Be Major Catalyst
- New Drug Approval Outlook: Teva's New Drug Application for long-acting schizophrenia drug olanzapine has been accepted by the FDA, and if approved, it is expected to significantly enhance patient adherence, driving sales growth and becoming the company's most meaningful catalyst.
- Specialty Drug Sales Surge: Teva's Austedo generated $2.26 billion in sales in 2025, marking a 34% year-over-year increase, with expectations to reach between $2.4 billion and $2.55 billion in 2026, showcasing strong momentum in the specialty drug sector.
- Biosimilar Market Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, potentially competing with Amgen and Johnson & Johnson, which will further solidify its position as the second-largest player in the biosimilar market.
- Investor Confidence Boost: Analysts are optimistic about Teva's future, with 12 out of 15 analysts rating the stock as a
See More
Teva Pharmaceutical Shares Surge 130% with Optimistic Outlook
- FDA Approval Catalyst: Teva's long-acting olanzapine injectable suspension NDA has been accepted by the FDA, with a decision expected later this year; approval could significantly enhance patient adherence, with combined annual sales with Uzedy projected to exceed $2 billion.
- Specialty Drug Sales Surge: Teva's specialty drug Austedo generated $2.26 billion in sales in 2025, a 34% year-over-year increase, with expectations for 2026 sales to rise between $2.4 billion and $2.55 billion, reflecting strong market demand and competitive positioning in the specialty drug sector.
- Biosimilar Expansion: Teva plans to launch six new biosimilars in 2026 and 2027, further solidifying its position as the second-largest player in the biosimilar market, with anticipated competition against giants like Amgen and Johnson & Johnson, driving future revenue growth.
- Market Risk Factors: Despite several catalysts propelling stock price growth, a market crash or significant pipeline issues could derail Teva's momentum; however, the company's pipeline is relatively de-risked, and with a forward P/E of only 11.7, it presents a compelling value investment opportunity.
See More
US Blockade of Strait of Hormuz Strains Relations with China and India
- Strained US-China Relations: The US blockade of the Strait of Hormuz not only intensifies pressure on Iran but also risks destabilizing the fragile relationship with China, particularly with a summit between Trump and Xi Jinping approaching, which could impact economic cooperation and strategic stability.
- Rising Energy Risks for India: After resuming oil and gas imports from Iran, India faces a conflict between US policy and its economic interests, especially regarding energy supply vulnerabilities, which may lead to further deterioration in relations with Washington.
- China's Resilience: Despite the energy shock, China's substantial oil stockpiles and diversified energy mix allow it to manage the situation relatively well, with expectations that it can compensate for lost Iranian oil through alternative sources and increased coal usage.
- India's Strategic Shortcomings: India's lack of strategic reserves for liquefied petroleum gas poses significant economic risks, particularly if Middle Eastern supplies are disrupted, potentially leading to shortages for households and businesses, which could affect social stability.
See More
Financial Stocks Underperform, Investors Remain Cautious
- Industry Challenges: Financial stocks have collectively dropped 8.8% over the past six months due to an unpredictable interest rate and inflation environment, significantly underperforming the S&P 500's 2.8% decline, indicating investor concerns about the sector's outlook.
- State Street's Lackluster Performance: With a market cap of $35.75 billion, State Street has seen only 3.6% annual revenue growth over the past five years, and its EPS growth of 9.1% annually falls short of the peer group average, reflecting limited growth potential compared to smaller competitors.
- Raymond James's Strong Growth: Raymond James, valued at $28.26 billion, has achieved an impressive 11.7% annual revenue growth over the last five years, bolstered by share buybacks that accelerated EPS growth, showcasing management's expertise in identifying profitable investments.
- Evercore's Market Share Gains: Evercore, with a market cap of $11.93 billion, has reported a remarkable 25.9% annual revenue growth over the last two years, with EPS increasing by 50.2% annually, indicating its success in capturing market share during the current cycle.
See More
